Amyris & Genome Compiler Partner to Commercialize DNA Construction Software Services for the Pharma and Biotech Industries
March 03 2015 - 8:00AM
Amyris, Inc. (Nasdaq:AMRS), an industrial bioscience company, and
Genome Compiler Corp., a synthetic biology platform company, have
entered into a collaboration agreement to integrate Amyris's
automated lab services with Genome Compiler's online design tools
and e-commerce platform to enable users to design and order DNA or
other biological products seamlessly.
This integration will provide a comprehensive solution from
design to delivery of first-of-its-kind integrated DNA design and
construction service, which promises to be more automated, less
expensive, and more sophisticated than current offerings. Customers
will benefit from Genome Compiler's software tools and Amyris's
rich libraries of verified genetic parts, DNA construction and
editing methods. This joint project is funded in part by a grant
from the Binational Industrial Research and Development Foundation
(BIRD Foundation), a U.S.-Israeli partnership between private
sectors to expand private high-tech industries.
"Amyris is committed to expanding the reach and access of our
world leading biofab for advanced DNA construction. We are excited
to partner with Genome Compiler to launch an integrated platform
for DNA design, construction and lab services. Similar to our
recently launched µPharm™ drug discovery and production platform,
this new partnership offers some of Amyris's proprietary automated
DNA engineering services to pharmaceutical and other biotech
companies for scientific discovery and creates opportunities for a
new revenue stream for our best-in-class technology platform," said
Joel Cherry, President of Research & Development at Amyris.
"At Genome Compiler, we bridge the gap between design and learn
iterations in the design-build-test-learn research and development
cycle, while providing users with an intuitive, comprehensive
synthetic biology platform solution. Making Amyris's best-in-class
biofab services broadly available as a service will enable
scientists to spend their time where it counts, on the science
itself instead of manual bench work," said Omri Amirav Drory, CEO
of Genome Compiler.
"Adding Amyris's advanced services to our providers' portfolio
will provide the pharma and biotech industries with a comprehensive
platform for all their synthetic biology needs. Customers would
benefit from direct connections to an array of DNA synthesis
providers and automation facilities, and from an extensive suite of
advanced bio-informatics tools and genetic repositories, all in one
platform," Drory concluded.
About the Companies
Amyris is a global renewable products company
providing sustainable alternatives to a variety of non-renewable
resources. Amyris uses its innovative bioscience technology to
convert plant sugars into hydrocarbon molecules. Amyris creates
ingredients and is commercializing its No Compromise® products in
the flavors and fragrances, cosmetics, specialty fluids, polymers,
lubricants, and fuels industries. Amyris Brasil Ltda., a subsidiary
of Amyris, oversees the establishment and expansion of Amyris's
production in Brazil. More information about Amyris is available at
www.amyris.com.
Genome Compiler is a leader in computer aided
design and collaboration platforms for the synthetic biology
industry. Based in Los Altos, CA and Tel-Aviv, Israel, Genome
Compiler's CAD tool and marketplace platform allows scientists in
the biotechnology, agriculture and pharmaceutical industries to
design, debug and compile biological code, to develop better
bio-based products faster. More information about Genome
Compiler is available at www.genomecompiler.com.
Forward-Looking Statements
This release contains forward-looking statements, and any
statements other than statements of historical facts could be
deemed to be forward-looking statements. These forward-looking
statements include, among other things, statements regarding future
events (such as the development and commercialization of a planned
DNA design and construction service and the anticipated benefits of
and customers for such a service) that involve risks and
uncertainties. These statements are based on management's current
expectations and actual results and future events may differ
materially due to risks and uncertainties, including those
associated with any delays or failures in development, production
and commercialization of products, liquidity and ability to fund
capital expenditures, Amyris's reliance on third parties to achieve
its goals, and other risks detailed in the "Risk Factors" section
of Amyris's quarterly report on Form 10-Q filed on November 7,
2014. Amyris disclaims any obligation to update information
contained in these forward-looking statements whether as a result
of new information, future events, or otherwise.
Amyris, the Amyris logo, µPharm, and No Compromise are
trademarks or registered trademarks of Amyris, Inc. All other
trademarks are the property of their respective owners.
CONTACT: Amyris, Inc.
Media & Investor Relations
+1 (510) 740-7481
info@amyris.com
Genome Compiler Corporation
Public Relations
+1 (510) 316-6584
info@genomecompiler.com
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amyris (NASDAQ:AMRS)
Historical Stock Chart
From Apr 2023 to Apr 2024